STAT+: With Successful Trials, Roche Takes Its MS Drug to Regulators, but Safety Questions Loom

Why It Matters

Fenebrutinib offers Roche a potential new revenue engine in a $15 billion MS market, yet safety concerns could impede regulatory clearance and market adoption.

Key Takeaways

• Fenebrutinib cut MS relapse rates in three Phase III trials.
• Trials showed slowed progression of disability for treated patients.
• Liver‑safety signals flagged; FDA previously rejected similar MS drug.
• Two drug‑related deaths reported in the latest data set.
• Approval could replace revenue from Roche’s aging MS therapy.

Pulse Analysis

Multiple sclerosis affects roughly 2.8 million Americans and remains a costly chronic condition, with global sales of disease‑modifying therapies exceeding $15 billion last year. Roche, a leader in neurology, has relied on its older MS product, Ocrevus, whose sales have plateaued as patents near expiry. The company has been hunting for a next‑generation blockbuster to sustain growth and offset the inevitable revenue dip. In this context, the experimental oral agent fenebrutinib, a Bruton's tyrosine kinase inhibitor, entered late‑stage development as a potential game‑changer.

Data from three Phase III trials released in April 2026 indicate that fenebrutinib reduced annualized relapse rates by roughly 30 percent and modestly slowed disability progression compared with placebo. The oral formulation also offered a convenient dosing schedule, a differentiator in a market dominated by injectables. Nonetheless, safety signals have emerged: elevated liver enzymes were observed in a subset of participants, and two deaths were classified as drug‑related. Regulators, particularly the FDA, have grown cautious after rejecting Sanofi’s similar therapy for comparable concerns, raising the bar for approval.

If approved, fenebrutinib could rejuvenate Roche’s MS franchise, potentially generating $2–3 billion in annual sales and cushioning the decline from Ocrevus. However, lingering safety questions may prompt stricter labeling or post‑marketing studies, which could dampen physician adoption and investor enthusiasm. Competitors such as Novartis and Biogen are also advancing oral agents, intensifying market pressure. Analysts will watch the regulatory filings closely, weighing the drug’s efficacy against its risk profile, as the outcome will influence Roche’s pipeline strategy and its standing in the neuro‑pharma sector.